Skip to content

Rescue of Infants With MCT8 Deficiency

Rescue of Infants With MCT8 Deficiency

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04143295
Acronym
DITPA
Enrollment
Unknown
Registered
2019-10-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency

Brief summary

Monocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively in males, disrupts development from before birth.

Interventions

DRUGDiiodothyropropionic acid (DITPA)

Drug Administration

Sponsors

Roy E. Weiss, M.D.
Lead SponsorOTHER

Eligibility

Sex/Gender
MALE
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* Genetic Confirmation: Male fetus or fetuses (including monozygotic twin pregnancies) must have a confirmed MCT8 gene mutation. * Family History: A previously born child or children with a severe, typical phenotype and an MCT8 gene mutation identical to that of the fetus. * Alternatively, the mother or a sister must have a relative with a known MCT8 defect. * Parental Decision: Parental refusal to terminate the pregnancy despite the diagnosis of MCT8 deficiency. * Compliance and Availability: Willingness of the parents to comply with all study procedures and ensure availability for the duration of the study.

Exclusion criteria

• Pregnancy-Related Factors: Dizygotic (non-identical) twin pregnancy (unless only one fetus is confirmed with the MCT8 mutation, and the unaffected fetus will not be treated). Parental decision to terminate the pregnancy. • Maternal Medical Conditions: Hyperthyroidism requiring treatment. Significant liver or kidney insufficiency. Congestive heart failure. Hyperemesis gravidarum unresponsive to treatment. * Significant cardiac conditions, including: * Atrial fibrillation or other arrhythmias. * Unstable angina. * Coronary heart disease. * Medications: Current use of sympathomimetic therapy. Anticoagulant therapy. Use of Cytochrome P450 2C9 (CYP2C9) inhibitors with a narrow therapeutic index. • Other Factors: Major illness or recent major surgery within four weeks of baseline visit 1, unrelated to MCT8 deficiency.

Countries

United States

Contacts

Primary ContactRoy E Weiss, M.D.
rweiss@med.miami.edu(305) 243-1944

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026